Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Almirall S.A.
0O9BAlmirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain. Address: Ronda General Mitre, 151, Barcelona, Spain, 08022
Analytics
Precio Objetivo de WallStreet
12.4 EURRelación P/E
–Rentabilidad por dividendo
1.64 %Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave 0O9B
Análisis de dividendos 0O9B
Aumento del dividendo durante 5 años
–Crecimiento continuo
1 AñoRatio de pago medio en 5 años
112 %Tendencia del payout 0O9B
Valoración de la acción 0O9B
Finanzas 0O9B
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |